Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note issued to investors on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Down 2.6 %

NASDAQ:AKTX opened at $2.24 on Friday. The firm has a fifty day simple moving average of $2.81 and a 200-day simple moving average of $2.85. Akari Therapeutics has a 12 month low of $1.08 and a 12 month high of $4.40.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.